Immunic (IMUX) Stock: Buy, Sell, or Hold?
$7.79
-0.33 (-4.06%)
âŧ
5d:
+6.42%
30d:
+16.97%
90d:
-51.49%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (44%)
Quality Score
51/100
Position
SLIGHTLY HIGH
30-Day Fair Range
$7.17 â $7.96
Position: SLIGHTLY HIGH
Forward P/E & Valuation
-3.3x
Next 12M consensus est.
Wall Street Target
$43.09
+453.2% upside
Options IV & Volume
66th pct IV
HIGH volume confirmation
Support / Resistance
$7.15 / $8.42
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: IMUX is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
Get Alerted When IMUX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: IMUX is currently trading at $7.79, which is considered slightly high relative to its 30-day fair value range of $7.17 to $7.96.
Technical Outlook: Technically, IMUX is in a strong downtrend. Immediate support is located at $7.15, while resistance sits at $8.42. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: IMUX scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $43.09 (+453.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IMUX is in a strong downtrend. Immediate support is located at $7.15, while resistance sits at $8.42. Short-term momentum is weak, with the stock down 4.1% recently.
Market Sentiment: IMUX scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $43.09 (+453.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$7.17 -
$7.96
Company Quality Score
51/100
(HOLD)
Options IV Signal
66th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
43.8%
Trading Range & Key Levels
30-Day Trading Range
$7.17 -
$7.96
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$2.02
(25.9%)
Support Level
$7.15
Resistance Level
$8.42
Current Trend
Strong Downtrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- NEUTRAL: Options fairly priced (IV 66th percentile)
- BEARISH: Weak technical setup (36/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.1%)
- BULLISH: Trading 453.2% below Wall St target ($43.09)
- WARNING: Composite score 51/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-3.30
Wall Street Target
$43.09
(+453.2%)
Share IMUX Analysis
Share this live IMUX analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (IMUX)
Bullish
2 Retail Mentions
Reddit / WSB Comments
1
Bullish
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 6, 2026
Daily AI digest
AI Retail Discussion Summary:
Immunic ($IMUX) is preparing a Phase 3 trial for its MS drug vidofludimus calcium in progressive MS, with first patients expected to enroll in H1 2027. The trial will evaluate disability improvements, and successful relapsing MS studies could lead to a potential market launch in 2028.
Key Retail Themes:
Clinical Trials
Progressive MS
Potential Market Launch
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 7:18 PM ET
Data refreshes hourly during market hours. Next update: 8:18 PM
Data refreshes hourly during market hours. Next update: 8:18 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMUX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 37 SELL |
|
REGN
Regeneron PharmaceuticalâĻ |
BUY
28 analysts |
$978 | 32 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 31 SELL |
|
DNTH
Dianthus Therapeutics InâĻ |
STRONG BUY
18 analysts |
$139 | 41 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 39 SELL |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive IMUX Research Pages
